April 2022

05 April 2022
Grenoble, France, 5th April, 2022 CYTOO and Astellas Gene Therapies (AGT) entered into a research collaboration in 2020 to select AGT’s AAV gene therapy clinical candidate to treat Duchenne Muscular Dystrophy (DMD). Today, AGT will present the results of this collaboration at the 2nd Gene Therapy for Muscular Disorders Summit in Boston. DMD is a rare and life-threatening genetic disorder that affects children–approximately 1 in 3,500 to 5,000 boys–and families. It is caused by mutations in the dystrophin gene that results in progressive muscle degeneration and weakness. By the early...